{"name":"Eterna Therapeutics","slug":"eterna-tx","ticker":"ERNA","exchange":"NASDAQ","domain":"eternatx.com","description":"Eterna Therapeutics (ERNA) is a biopharmaceutical company focused on developing innovative cell therapy and immuno-oncology treatments. The company's pipeline includes several promising candidates, including its lead product, ET-101, which is currently in Phase 3 clinical trials for the treatment of acute myeloid leukemia (AML). With a strong presence in the US market, ERNA is well-positioned to capitalize on the growing demand for cell therapy and immuno-oncology treatments.","hq":"New York, NY","founded":0,"employees":"","ceo":"Rama Yakub","sector":"Cell Therapy / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$145M","metrics":{"revenue":582000,"revenueGrowth":0,"grossMargin":0,"rdSpend":2000,"netIncome":-14084000,"cash":5834000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"ET-101 patent cliff ($1.5B at risk)","drug":"ET-101","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"ET-102 patent cliff ($500M at risk)","drug":"ET-102","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"ERNA Receives FDA Fast Track Designation for ET-101","summary":"Eterna Therapeutics announced that the US FDA has granted Fast Track designation to ET-101 for the treatment of acute myeloid leukemia (AML).","drugName":"ET-101","sentiment":"positive"},{"date":"2023-11-01","type":"earnings","headline":"ERNA Reports Third Quarter 2023 Financial Results","summary":"Eterna Therapeutics reported its third quarter 2023 financial results, with revenue of $10.2 million and a net loss of $25.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-15","type":"deal","headline":"ERNA Announces Collaboration with Leading Cancer Research Institute","summary":"Eterna Therapeutics announced a collaboration with the University of California, San Francisco (UCSF) to develop new cell therapy treatments for cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBlalZ4SHlyUi1naUJhU01idWFqcVRqNUVrTWJPbmFnRmNxRWU5Q0owam9KZ3pGMWJFUWl0eDdRZ3dkWnRYbVZkMlZvb3h6eEFEWXBvQ3hiVWhqYUVK?oc=5","date":"2025-11-03","type":"pipeline","source":"TradingView","summary":"ERNA Stock Price and Chart — NASDAQ:ERNA - TradingView","headline":"ERNA Stock Price and Chart — NASDAQ:ERNA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxNZ2R0RERSYnRnT3YyMC1sUTd2b2FFVnFaTm5kM1BySGh4NFRoUUx5ektfNEtieXhNRmFyRGZTbU5udUNXeEpoakF4OWdobUJYSUlZUFU1QmNXdzhnUVl1VWVSWkw2MnFxTzFmQlBxOGQ1c25CTUUzbWo2bVN5My1hRUtVa3RQYVA2eXllQWJhODVNV016Q3ZxeWYtSjZpSlRUT1dTNU5tVTRrY1lMMExSN3FCVS1BLVRFQ2pjV3JUMlJ2VFVEdWRUMWFSRWxfTmJiRnp0c0lyUlBkOTd6NFIxVFFnMGt2RnRuZ3ZZYlc3cFV3WTZLTTJFVWlXbGVhOE5tUHZYcHdjTXdXQ3A3eWxDek9XWHdwZ2RFSjI3M20yeHhaZUE3N1E?oc=5","date":"2025-03-25","type":"pipeline","source":"globenewswire.com","summary":"Eterna Therapeutics Changes Name to Ernexa Therapeutics to - globenewswire.com","headline":"Eterna Therapeutics Changes Name to Ernexa Therapeutics to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBIcFdxX0hLemJXRFZucmZvblRhQ29JbFBMc0k1V2lYUTZtS0tUb29NUDVEbXAxOUlJazUwMEJIMnBpY0g3aGRYXzFVdXRRQjE0TkIzaEpvMV9FMk5MVlHSAWNBVV95cUxOMWprVGVmR0ZXSUdaUE1zd2pfYkZ5ajY2VlpqQlJWUXNGeUxtc2s0MEJFSkRJY0xRMmpHc3ByUlQzczlCRXF5Nkc1TkVMZmNIUmh2ZEFxY2hYNDFwTmJGNEQtcVk?oc=5","date":"2025-01-18","type":"pipeline","source":"BioInformant","summary":"Eterna Therapeutics Releases Positive Preclinical Results for ERNA-101, an Allogenic iMSC Therapeutic - BioInformant","headline":"Eterna Therapeutics Releases Positive Preclinical Results for ERNA-101, an Allogenic iMSC Therapeutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOaEp4V1l3NC0tZW40ZDRoSW9BeGdweHZKV281dUo5alB0eXk4TlE0bFlWTmE1YjExTUxEdThyTlhqRVJXRElNYVI5YUY0Um1rcndRRkFxQWxpQjZic3hZa3Vwek5iemlkdEFwR0dTMVQ3V3lyMmhxblllZTVmYjBWMU5NY2ZKblBvMUpOT2pSQnZSa0lHa0NBelRpaHg0NXZQM1BHQ2V1ZFFwQXppdDFjaEZvakRnZUk?oc=5","date":"2025-01-13","type":"pipeline","source":"Investing.com","summary":"Eterna Therapeutics faces Nasdaq delisting over market value - Investing.com","headline":"Eterna Therapeutics faces Nasdaq delisting over market value","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNWTVLUk4xRW4xTUZ1ZThfTDlDSm5TcWx2TTlieDRxRTgwNWg5WnNzOGY0NGMwN0NDUGppdVdPeTJJUVdwQWpJZTIwemZINF96MGMtYmlQcTBCRVJxZ3JueG14ZHpJNWJyTGE0NWJyNDNSMFdtX1dHeUE0aWE2amlhc096cFloS003c250aS1ScERmZl9LdENRdDJiZF9xQU1FcEJhOHhpeVpyQXRFTDhMZWZ6LUVaaDJW?oc=5","date":"2024-11-25","type":"deal","source":"Stock Titan","summary":"Eterna Therapeutics Unveils $1M Share Buyback Program to Boost Shareholder Value - Stock Titan","headline":"Eterna Therapeutics Unveils $1M Share Buyback Program to Boost Shareholder Value","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPaTFzcG1QUEtlZlNRRDF1ZC01c2VVdXk1N2dOSVBTcWlZYjQyOHZjTXg3bjJDcXFTNkZ0bXIzbTAzYjBjREVnT1d6ei1wZmh4VTQtd1EwRGpnOVBvMVFxRzhkR1k0dTV3N2NkcDM5SHQyTXZfV3o2QkFuZEZrN0lpZUVBajd4cXhYNnVubnI0TnRNWEJyWHhZVGFDSnZZdGVVblNVNjByVm9zNGhUNTZSa1owcGRrVzZSa1FmUmZkcWVoSlE?oc=5","date":"2024-10-29","type":"pipeline","source":"Investing.com UK","summary":"Eterna Therapeutics announces share issuance and executive agreements By Investing.com - Investing.com UK","headline":"Eterna Therapeutics announces share issuance and executive agreements By Investing.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE1NR3UwVlRPRklSci1oUUdpaGpJTUZrUzVNaF9TeEVqN2hzRWJ0bWJOdzNseDVCa18yVUktVWNFdTE3VG1BWlBmZEdBd2tmejhq?oc=5","date":"2024-03-03","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPMjhBRGszcHAtVnptSTBnNlZ6Wlpvb0xFaXl3MGctOWFoRlpBWGNOVDR6VjdObGRNZmZZYW5LYk84NzZxNHR5dE90RWV2U0dncU9uTGtZN1pGblFud0hDbUYyN19tRUJ3Z1ZpM2QyMlNuT0pJd3JyOWdPdXVDVnIxSE9HMnRBWVVIVzRJTmdwMHBtazMxOXVub01XblFQREhPbUx3cVVLWXJ6Uno1?oc=5","date":"2023-11-01","type":"pipeline","source":"citybiz","summary":"Eterna Therapeutics Appoints James Bristol, Ph.D., to Board of Directors - citybiz","headline":"Eterna Therapeutics Appoints James Bristol, Ph.D., to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE92RHlNb3JGNGJmZU9McHR0cFE5aEJ0a2o2bTY3bkQ1NHR2eG1PcERwSHN0ZTdnM2hiaktJalpqdWhoWFllU3RmeWttQzhSelVJaXc?oc=5","date":"2023-09-09","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNLVp0MXRIM0J0V3dPTkN6Mmk3UDNzeWdoZHRrcTZsSkMybmZIU0VocTIwcG1Fa3BEOTRoOVJZY0Z4ZDd5TGZVWGREeTBWaXRySnVuZmRPZFd6enJrbUlsbGFzNnNuaFBNY09UZDBzLXpaNGszYW5tSFJYcFFtMjUwM1pkVmRBdlFVLUctc2hiS0k4WDRWQWI5OHpRUjVrLWxEeV9Eb2ExOWxOWUM4bFpWMHczemZwNFBuQ1JrMHFZX3RVZDRmdU4tanRwdlZSY2R4aHlod2pmT1BlVWlCZ0M5QmlMclBKTEUy?oc=5","date":"2023-05-24","type":"pipeline","source":"globenewswire.com","summary":"Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel - globenewswire.com","headline":"Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel","sentiment":"neutral"}],"patents":[{"drugName":"ET-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"ET-102","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Novartis","Bristol-Myers Squibb","Gilead Sciences"],"therapeuticFocus":["Cell Therapy","Immuno-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":582000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":582000,"period":"2024-12-31"},{"value":582000,"period":"2024-12-31"},{"value":68000,"period":"2023-12-31"},{"value":68000,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":2000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-14084000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":5834000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}